InfertilityNCT03678558
Oocyte Vitrification Aided With Cytochalasin B
A study testing Cytochalasin B supplemented vitrification medium in people with Infertility, run by Ibn Sina Hospital at 1 site in Egypt.
Trial summary
Using the cytoskeleton Stabilizer the Cytochalasin B would improve the outcome of oocyte vitrification. Read more about this study
- Who is it for?
- Ages 18 to 42 years, women only
- Conditions the study is for
- Infertility
- What is being tested?
- Cytochalasin B supplemented vitrification medium
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 612 participants
- Where
- 1 siteEgypt
- Study dates
- 25 Sep 2018to 5 Aug 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 42 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- indication for oocyte vitrification
Who cannot join
- -
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Cytochalasin B for Oocyte Vitrification
Using the cytoskeleton Stabilizer the Cytochalasin B would improve the outcome of oocyte vitrification.
- Conditions
- Infertility
- Being tested
- Cytochalasin B supplemented vitrification medium
- Medical subject headings
- Infertility
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cytochalasin B supplemented vitrification mediumOther
Vitrification of human oocyte in medium supplemented with Cytochalasin B
| Study group | Role | What they receive |
|---|---|---|
| Cytochalasin B supplemented vitrification medium | Experimental | Not described Receives: Other: Cytochalasin B supplemented vitrification medium |
| Vitrification medium with no supplementation | No intervention | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
survival after thawing
Measured: 6 days of culture
Secondary outcomes (5)
fertilization rate
Measured: 6 days of culture
Rates of blastocyst formation and quality
Number of formed blastocyst and blastocyst with high-quality per fertilized oocytes
Measured: 6 days of culture
embryo utilisation rate
Measured: 6 days of culture
clinical pregnancy rate
Measured: three months
ongoing pregnancy rate
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Sep 2018
- Study start25 Sep 2018
- Primary completion5 Aug 2019
- Study completion5 Aug 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for InfertilityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 612 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ibn Sina Hospital
- Sponsor type
- Other government
- Collaborators
- Banoon IVF Center
- Responsible party
- Principal investigator, Muhammad Fawzy, Ibn Sina Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03678558
- Sponsor's protocol ID
- IbnSina-Oocyte-CB
- Status last verified
- Aug 2019
- First submitted
- 17 Sep 2018
- Last updated
- 7 Aug 2019
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Aug 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cytochalasin B for Oocyte Vitrification
- ClinicalTrials.gov ID
- NCT03678558
- Acronym / sponsor ID
- IbnSina-Oocyte-CB
- Conditions
- Infertility
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 612 participants (actual)
- Lead sponsor
- Ibn Sina HospitalOther government
- Collaborators
- Banoon IVF Center
- Study start
- 25 Sep 2018 (actual)
- Primary completion
- 5 Aug 2019 (actual)
- Study completion
- 5 Aug 2019 (actual)
- First posted
- 19 Sep 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Using the cytoskeleton Stabilizer the Cytochalasin B would improve the outcome of oocyte vitrification.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Cytochalasin B supplemented vitrification medium | Experimental | Other: Cytochalasin B supplemented vitrification medium |
| Vitrification medium with no supplementation | No intervention | – |
Who may qualify
- Ages
- 18 to 42 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- indication for oocyte vitrification
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cytochalasin B supplemented vitrification mediumVitrification of human oocyte in medium supplemented with Cytochalasin B | Other | Cytochalasin B supplemented vitrification medium |
Primary outcome
survival after thawing
Time frame: 6 days of culture
5 secondary outcomes
fertilization rate
Time frame: 6 days of culture
Rates of blastocyst formation and quality
Time frame: 6 days of culture
embryo utilisation rate
Time frame: 6 days of culture
clinical pregnancy rate
Time frame: three months
ongoing pregnancy rate
Time frame: 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Aug 2019.
- Individual participant dataSharing planned: No
Related trials for Infertility
RecruitingPhase 3
A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)
Infertility
Active, not recruitingObservational study
Fresh Versus Vitrified-Warmed Donor Oocytes: Embryological and Clinical Outcomes
Infertility, Donor Oocyte Assisted Reproduction
RecruitingObservational study
Safety and Efficacy of Corifollitropin Alfa N02 Injection in Elderly Women Undergoing Assisted Reproductive Technology (ART)
Infertility
Active, not recruiting
Automation of the In Vitro Fertilization Laboratory
Infertility, ART
RecruitingObservational study
Inherited Reproductive Disorders
Genetic Disorder, Infertility
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Cytochalasin B supplemented vitrification medium in people with Infertility, run by Ibn Sina Hospital at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Aug 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
survival after thawing (time frame: 6 days of culture). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Aug 2019.